Bridge Therapy Between Induction, ASCT May Slow Neuroblastoma
Bridging therapy before ASCT improved event-free survival for patients with stable metastatic disease at the end of induction.
Bridging therapy before ASCT improved event-free survival for patients with stable metastatic disease at the end of induction.
Transplant after a 3-drug induction regimen can prolong progression-free survival, compared with triplet induction alone, in patients with multiple myeloma.
Initiation of revaccination appears to be delayed for a significant portion of pediatric patients following allo-HSCT.
Researchers sought to determine whether there were long-term benefits for patients with hematologic malignancies treated with allo-HSCT and omidubicel.
Researchers sought to determine whether adding eprenetapopt to maintenance azacitidine after HCT would be effective in patients with AML or MDS.
There was no significant difference in transplant-related mortality or overall survival.
The approach resulted in low rates of graft failure, viral infections, and relapse.
Researchers sought to determine the costs of care and health resource use of patients with hematologic malignancies undergoing allo-HCT.
Steroid-refractory acute GVHD is associated with high mortality rates in pediatric patients, despite second-line treatment.
The 1-year progression-free survival rate was 45%, and the 1-year overall survival rate was 59%.